{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:40:22Z","timestamp":1768808422877,"version":"3.49.0"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Viele PatientInnen mit visusgef\u00e4hrdender nicht infekti\u00f6ser Uveitis bed\u00fcrfen, um eine Remission ihrer Uveitis zu erreichen, einer Behandlung mit DMARDs. Obwohl herk\u00f6mmliche DMARD-Therapien\n\t\t\t\t\tin einem gro\u00dfen Teil dieser PatientInnen eine hochpotente Therapie darstellen, ist in einzelnen F\u00e4llen aufgrund eines unzureichenden Ansprechens oder unerw\u00fcnschter Wirkungen ein\n\t\t\t\t\tTherapiewechsel erforderlich. Januskinase-Inhibitoren (JAKI) sind in der Rheumatologie, Gastroenterologie und Dermatologie bereits f\u00fcr mehrere autoimmune Erkrankungen zugelassen. Nun steht\n\t\t\t\t\tein Zulassungsprozess f\u00fcr ausgew\u00e4hlte Uveitisentit\u00e4ten an. Wirkmechanismus: JAKI \u00fcben ihre Wirkung \u00fcber die Hemmung der Phosphorylierung von Transmembranproteinen, den Januskinasen aus. Dies\n\t\t\t\t\tf\u00fchrt zu einer fehlenden Aktivierung von Transkriptionsfaktoren und damit zur verminderten Zytokinexpression und Entz\u00fcndungshemmung. JAKI stellen in der Rheumatologie, Gastroenterologie und\n\t\t\t\t\tDermatologie einen \u00e4u\u00dferst effektiven neuen therapeutischen Ansatz dar. Sie sind zur Behandlung bei rheumatoider Arthritis, Psoriasis-Arthritis, ankylosierender Spondylitis, Colitis ulcerosa\n\t\t\t\t\tund dem atopischen Ekzem bereits zugelassen. In bisherigen Vergleichsstudien zu etablierten Biologika konnte teilweise ein besseres therapeutisches Ansprechen beschrieben werden. Aus\n\t\t\t\t\tpublizierten Fallberichten wurde auch bei Uveitispatienten, die auf klassische und biologische DMARDs unzureichend ansprachen, eine Kortisoneinsparung und Reizfreiheit erzielt.\n\t\t\t\t\tZulassungsstudien bei JIA-assoziierter und ANA-positiver anteriorer Uveitis sind im Prozess. Zusammenfassend stellen JAKI eine innovative Therapieoption bei Patienten mit nicht infekti\u00f6ser\n\t\t\t\t\tUveitis dar, bei denen Kontraindikationen gegen die Verwendung oder ein unzureichender Effekt von DMARDs bestehen.<\/jats:p>","DOI":"10.1055\/a-1741-8104","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:41:35Z","timestamp":1649983295000},"page":"695-701","source":"Crossref","is-referenced-by-count":14,"title":["Januskinase-Inhibitoren: Next-Generation-Therapie der Uveitis"],"prefix":"10.1055","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1704-0183","authenticated-orcid":false,"given":"Yosuf","family":"El-Shabrawi","sequence":"additional","affiliation":[{"name":"Augenheilkunde, Klinikum Klagenfurt am W\u00f6rthersee, \u00d6sterreich"},{"name":"Augenheilkunde, Medizinische Universit\u00e4t Graz, \u00d6sterreich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rath","sequence":"additional","affiliation":[{"name":"Rheumatologie, Fachklinik Bad Bentheim, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnd","family":"Heiligenhaus","sequence":"additional","affiliation":[{"name":"Augenabteilung, St.\u00a0Franziskus Hospital, M\u00fcnster, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.7604283","article-title":"Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I","volume":"269","author":"T S Migone","year":"1995","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"P Macchi","year":"1995","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate\n\t\t\t\t\tresponse to disease-modifying antirheumatic drugs","volume":"64","author":"R Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Behcet\u02bcs syndrome","volume":"79","author":"J Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"P Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"ii31","DOI":"10.1093\/rheumatology\/keab265","article-title":"Clinical use of Jak 1 inhibitors for rheumatoid arthritis","volume":"60","author":"P Nash","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world\n\t\t\t\t\tdata","volume":"79","author":"P Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"N Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref9","volume-title":"Tofacitinib for the Treatment of Polyarthricular Course Juvenile Idiopathic Arthtitis: Results of a Phase randomised double-blind, Placebo controlled Study","author":"H L Brunner","year":"2019"},{"key":"ref10","first-page":"641","article-title":"Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells","volume":"26","author":"S J Bing","year":"2020","journal-title":"Mol Vis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"M A Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis","volume":"27","author":"P Bauermann","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"E Miserocchi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/acr.24007","article-title":"Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After\n\t\t\t\t\tSwitching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate","volume":"72","author":"R Fleischmann","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00108-017-0345-6","article-title":"[Janus kinase inhibitor baricitinib for rheumatoid arthritis: Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in\n\t\t\t\t\tpatients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)]","volume":"58","author":"R Alten","year":"2017","journal-title":"Internist (Berl)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40744-018-0110-x","article-title":"Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A\u00a0Subset\n\t\t\t\t\tAnalysis","volume":"5","author":"A F Wells","year":"2018","journal-title":"Rheumatol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40744-021-00317-9","article-title":"Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2\u2009mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies\n\t\t\t\t\tand One Long-Term Extension Study","volume":"8","author":"A F Wells","year":"2021","journal-title":"Rheumatol Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"G AM Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib","volume":"136","author":"S Sarny","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2020-7-5","DOI":"10.7573\/dic.2020-7-5","article-title":"Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III\n\t\t\t\t\trandomized controlled trial in Central and Eastern European patients","volume":"9","author":"K Pavelka","year":"2020","journal-title":"Drugs Context"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1093\/rheumatology\/keaa893","article-title":"Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis","volume":"60","author":"A B Avci","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3390\/microorganisms9071481","article-title":"Ruxolitinib Alleviates Uveitis Caused by Salmonella typhimurium Endotoxin","volume":"9","author":"L Du","year":"2021","journal-title":"Microorganisms"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data","volume":"13","author":"R Harrington","year":"2020","journal-title":"J Inflamm Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1007\/s10067-021-05911-4","article-title":"Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review","volume":"40","author":"S Mori","year":"2021","journal-title":"Clin Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"W Xie","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","article-title":"Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis","volume":"2","author":"M C Genovese","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2939370","DOI":"10.1155\/2016\/2939370","article-title":"SOCS1 Mimetic Peptide Suppresses Chronic Intraocular Inflammatory Disease (Uveitis)","volume":"2016","author":"C He","year":"2016","journal-title":"Mediators Inflamm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2217\/imt-2020-0153","article-title":"How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology","volume":"12","author":"T Y Jessica Chang","year":"2020","journal-title":"Immunotherapy"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"Covid-19 in Immune-Mediated Inflammatory Diseases \u2013 Case Series from New York","volume":"383","author":"R Haberman","year":"2020","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab879","article-title":"Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination","author":"L Iancovici","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1741-8104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T22:44:13Z","timestamp":1652222653000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1741-8104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":30,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2022,5,10]]},"published-print":{"date-parts":[[2022,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1741-8104","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}